BI’s Cyltezo Becomes 15th EU Biosimilar This Year, Adds To Pressure On Humira

Boehringer Ingelheim has received its first EU biosimilar approval: Cyltezo, a version of AbbVie’s blockbuster drug Humira. The product will not be launched until after expiry of the adalimumab SPC in October 2018.